ViiV Healthcare1, a joint venture in which GSK is the majority shareholder, released the interim results from the DAWNING study2 at the recent International AIDS Conference
These press releases are intended for business journalists and analysts/investors
GSK China partners with Ali Health to launch innovative online service platform to improve adult vaccination consultation experience
Today, GSK China and Ali Health jointly announced a strategic partnership to launch an innovative adult vaccination service system.
GSK today announced that Triumeq (generic name: dolutegravir, abacavir and lamivudine all-in-one tablet), the innovative antiretroviral (ARV) drug by its subsidiary joint venture ViiV Healthcare1, was granted approval by the China Food and Drug Administration (CFDA).
Today, on the occasion of World Hepatitis Day, under the guidance and support of the National Health and Family Planning Commission (NHFPC), GSK and the China Health Promotion Foundation (CHPF) signed a Letter of Intent.
The Ministry of Human Resources and Social Security (MOHRSS) today announced the results of the national health insurance negotiations, and two GSK products, Tykerb (Lapatinib) and Seroxat CR (Paroxetine), are included in the national reimbursement drug list (NRDL).
GSK announces strategic partnership with academia to co-develop health big-data system and upgrade the management of respiratory diseases
The programme will cover 5000 COPD patients and 60,000 athma patients.
The National Preventive Vaccination Services and Management Training Programme, helmed by the Chinese Preventive Medicine Association under the guidance of the National Health and Family Planning Commission (hereinafter referred to as NHFPC), with the support of the China Centre for Disease Control and Prevention and the aid of GSK, was officially kicked off today.